The new machinery, called a "chimeric antigen receptor" or "Car," transforms a diverse T-cell population into Car-T, where the engineered cells all respond to the same cancer-associated marker. Both ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to ...
In this free webinar, learn about parameters that limit the efficacy of current chimeric antigen receptor (CAR) T-cell therapies and enable the development of CAR T-cells with enhanced performance.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to ...
Anixa Biosciences begins patient dosing in third cohort in ongoing phase 1 trial of novel CAR-T therapy for recurrent ovarian cancer: San Jose, California Wednesday, November 20, ...
We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where ...
The Leukemia & Lymphoma Society (LLS) will present new data from its Beat AML® Master Clinical Trial and Pediatric Acute ...
Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.